Coordinates: 245831.9N 1213154.0E. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. ITI maintains its headquarters in Rockville, Maryland. Pay, Holidays and PTO appear to be very good. All answers shown come directly from Immunomic Therapeutics Reviews and are not edited or altered. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. November 30, 2021, 7:01 PM UTC. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. ITI-3000 Merkel Cell Carcinoma - pDNA. Immunomic Therapeutics is a biotech company committed to patients. Work Here? Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Sia Anagnostou ITI-1000 GBM - Cell Therapy. ITI maintains its headquarters in Rockville, Maryland. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. Very family oriented. Juniper Point Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. While research is the essential engine that drives our technology forward, our efforts in process development, manufacturing management, and regulatory affairs are critical factors that advance the Immunomic Therapeutics vision. 438 followers 429 connections. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. ITI maintains its headquarters in Rockville, Maryland. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Operating Status Active. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. Email credentials to careers@immunomix.com. Description. But a few things must happen first. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. Jan 2006 - Present17 years 2 months. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Claim your Free Employer Profile. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Curr Opin Immunol. Harnessing the immune system to achieve deep and durable clinical responses in cancer. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. For more information, please visit www.immunomix.com. ICT has established a broad portfolio of CAR-T products to treat cancer patients. At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. This is the Immunomic Therapeutics company profile. Melody Carey ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. aanagnostou@immunomix.com It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. Founded Date 2015. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . ITI-3000 Merkel Cell Carcinoma - pDNA. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. Where the organization is headquartered (e.g. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. mcarey@rxir.com Active, Closed, Last funding round type (e.g. all maps fatal bullet; who is running for senate in maryland 2022 We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. 858-366-3243, Internet Explorer presents a security risk. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). 2017 Aug;47:85-92. / Oct 13, 2015. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. In addition, ITI-1001 represents a far more cost-effective approach. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. ITI-1001 GBM - pDNA. 2015 Mar 19;519(7543):366-9. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Melissa Kemp Animal Health All. Immunomic Therapeutics, Inc. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI-2000 provides an UNITE platform address for HPV+ cancers. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. ITI-1000 GBM - Cell Therapy. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Melody Carey Rockville, Maryland, 20850, United States. View detailed 028300.KR description & address. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. We provide a professional and challenging work environment . The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Background. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Amy Conrad 917-322-2571, Internet Explorer presents a security risk. Our goal is to overcome the limitations of current immuno-oncology therapies by . I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. 2006 Aug 15;177(4):2265-75. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. 15010 Broschart Road Suite 250. 301-968-3501, ITI Media: Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . 301-968-3501 Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. ITI Company: We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. 2017 Apr 15;23(8):1898-1909. We provide a professional and challenging work environment . The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Stock ticker symbol (e.g. activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. immunomic therapeutics crunchbase. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Contact Email info@immunic.de. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI-ID Candidate Multiple infectious diseases. 2003 Sep 26;278(39):37926-36. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. To explore Immunic Therapeutics's full profile, request access. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. mkemp@immunomix.com CONTACT US. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. Nature. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Immunomic Therapeutics' nucleic acid vaccines have the . We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Hershey, PA & Rockville, MD and Tokyo, Japan. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Hum Vaccin Immunother. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is .